Literature DB >> 10662506

Prion protein peptides: optimal toxicity and peptide blockade of toxicity.

D R Brown1.   

Abstract

In prion disease neurodegeneration requires deposition of the abnormal isoform of the prion protein (PrP(Sc)) within nervous tissue. In vitro PrP(Sc) has neurotoxicity that can be mimicked by peptides based on part of its sequence. In this investigation the region of the protein required for maximal neurotoxicity was precisely determined. The optimal neurotoxic peptide was found to contain amino acids 112-126 of the human sequence. The sequence AGAAAAGA was found to be necessary but not sufficient for a neurotoxic effect. The AGAAAAGA peptide blocked the toxicity of PrP106-126, suggesting that this sequence is necessary for the interaction of PrP106-126 with neurons. These results suggest that targeting or use of the AGAAAAGA peptide may represent a therapeutic opportunity for controlling prion disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10662506     DOI: 10.1006/mcne.1999.0796

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  12 in total

1.  Competing intrachain interactions regulate the formation of beta-sheet fibrils in bovine PrP peptides.

Authors:  Abdessamad Tahiri-Alaoui; Mario Bouchard; Jesús Zurdo; William James
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

2.  Optimal molecular structures of prion AGAAAAGA amyloid fibrils formatted by simulated annealing.

Authors:  Jiapu Zhang
Journal:  J Mol Model       Date:  2010-04-22       Impact factor: 1.810

3.  Characterization of PRNP and SPRN coding regions from atypical scrapie cases diagnosed in Poland.

Authors:  Agata Piestrzyńska-Kajtoch; Artur Gurgul; Mirosław P Polak; Grzegorz Smołucha; Jan F Zmudziński; Barbara Rejduch
Journal:  Mol Biol Rep       Date:  2011-06-15       Impact factor: 2.316

4.  Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells.

Authors:  Valentina Villa; Stefano Thellung; Alessandro Corsaro; Federica Novelli; Bruno Tasso; Luca Colucci-D'Amato; Elena Gatta; Michele Tonelli; Tullio Florio
Journal:  Mol Neurobiol       Date:  2014-11-18       Impact factor: 5.590

5.  PrPSc-like prion protein peptide inhibits the function of cellular prion protein.

Authors:  D R Brown
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

6.  Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies.

Authors:  Agata Mata; Laura Urrea; Silvia Vilches; Franc Llorens; Katrin Thüne; Juan-Carlos Espinosa; Olivier Andréoletti; Alejandro M Sevillano; Juan María Torres; Jesús Rodríguez Requena; Inga Zerr; Isidro Ferrer; Rosalina Gavín; José Antonio Del Río
Journal:  Mol Neurobiol       Date:  2016-10-10       Impact factor: 5.590

7.  The mechanisms of [URE3] prion elimination demonstrate that large aggregates of Ure2p are dead-end products.

Authors:  Leslie Ripaud; Laurent Maillet; Christophe Cullin
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

8.  Conformational polymorphism of the amyloidogenic peptide homologous to residues 113-127 of the prion protein.

Authors:  K S Satheeshkumar; R Jayakumar
Journal:  Biophys J       Date:  2003-07       Impact factor: 4.033

9.  Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein.

Authors:  E Hanan; S A Priola; B Solomon
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 4.231

10.  Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein.

Authors:  Silvia Vilches; Cristina Vergara; Oriol Nicolás; Gloria Sanclimens; Sandra Merino; Sonia Varón; Gerardo A Acosta; Fernando Albericio; Miriam Royo; José A Del Río; Rosalina Gavín
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.